...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >FORMULATION, OPTIMIZATION, AND CHARACTERIZATION OF BIOCOMPATIBLE INHALABLE D-CYCLOSERINE-LOADED ALGINATE-CHITOSAN NANOPARTICLES FOR PULMONARY DRUG DELIVERY
【24h】

FORMULATION, OPTIMIZATION, AND CHARACTERIZATION OF BIOCOMPATIBLE INHALABLE D-CYCLOSERINE-LOADED ALGINATE-CHITOSAN NANOPARTICLES FOR PULMONARY DRUG DELIVERY

机译:生物相容性可吸入D-环丁氨酸负载的藻酸盐-壳聚糖纳米颗粒的配制,优化和表征

获取原文

摘要

Objective: To prepare Nanoparticulate dosage form having improved drug bioavailability and reduced dosing frequency of antitubercular drugs which will helps in improving patient compliance in the treatment of multi-drug resistant tuberculosis (MDR-TB). Methods: Ionotropic gelation method was used to prepare D-cycloserine (D-CS)-loaded alginate-chitosan nanoparticles, and the particles are characterized by their particle size and morphology using particle size analyzer and scanning electron microscopy (SEM). X-ray diffraction (XRD), differential scanning calorimetry (DSC), and Fourier-transformed infrared (FTIR) studies were used to determine drug-polymer interactions and drug entrapment. Entrapment efficiency, drug loading (DL), particle size, and zeta potential of nanoparticles were also studied. The 2 factorial designs of experiments by Design-Expert ? V9 were used to optimize the particle size and entrapment efficiency of nanoparticles. Results: The optimized batch had shown the entrapment efficiency of 98.10±0.24% and DL of 69.32±0.44% with particle size and zeta potential as 344±5 nm and ?42±11.40 mV, respectively. DSC, FTIR, and XRD studies confirmed the drug entrapment within nanoparticle matrix. SEM results showed spherical-shaped particles. Sustained release of drug from the nanoparticles was observed for 24 hrs period. Respirable fraction up to 52.37±0.7% demonstrates the formulation suitability for deep lung delivery. Lung inflammatory study showed a less inflammatory response. Conclusion: Ionotropic gelation method can be used to prepare biocompatible particles with a high entrapment efficiency, DL, optimum particle size, and controlled release characteristics, which can serve as a convenient delivery system for D-CS and could be a potential alternative to the existing conventional therapy in MDR-TB.
机译:目的:制备具有改善的药物生物利用度和减少的抗结核药物给药频率的纳米颗粒剂型,这将有助于提高患者在耐多药结核病(MDR-TB)治疗中的依从性。方法:采用离子凝胶法制备负载D-环丝氨酸(D-CS)的藻酸盐-壳聚糖纳米粒,并利用粒度分析仪和扫描电镜(SEM)对它们的粒径和形貌进行表征。 X射线衍射(XRD),差示扫描量热法(DSC)和傅立叶变换红外(FTIR)研究用于确定药物-聚合物相互作用和药物截留。还研究了纳米粒的包封效率,载药量(DL),粒径和ζ电位。设计专家的2种析因设计实验V9用于优化纳米颗粒的粒径和包封效率。结果:优化后的批料的包封率分别为98.10±0.24%和DL为69.32±0.44%,粒径和zeta电位分别为344±5 nm和?42±11.40 mV。 DSC,FTIR和XRD研究证实了纳米颗粒基质中的药物截留。 SEM结果显示球形颗粒。在24小时内观察到药物从纳米颗粒的持续释放。高达52.37±0.7%的可吸入分数表明该制剂适用于深部肺部递送。肺部炎症研究显示较少的炎症反应。结论:离子凝胶法可用于制备具有高包封率,DL,最佳粒径和控释特性的生物相容性颗粒,可作为D-CS的便捷递送系统,并可作为现有的潜在替代方法耐多药结核病的传统疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号